Enbrel

Type: Product
Name: Enbrel
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Regulated genes in psoriatic skin during treatment with fumaric acid esters.

Br J Dermatol.2014;171(4):732-41  (ISSN: 1365-2133)Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EPBACKGROUND:Fumaric acid esters (FAEs) are widely used in Europe for the treatment ... [Published British Journal of Dermatology - Oct 18 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

New treatments help seniors live longer

The latest prescription drugs, surgeries, medical procedures and high-tech devices are helping seniors to live longer, healthier lives.Dr. Panayiotis Tsitouras, an OU Physicians’ geriatrician, said the proper approaches toward healthier aging include ... [Published NewsOK.com - Oct 18 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

RLO Announces Class Action Lawsuit By Enbrel Patient Against Immunex and Caremark CVS Over Mail Order Caremark Prescriptions

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled ... [Published PRWeb - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 17 2014 - 1 reports

UPDATE 1-Novartis psoriasis drug benefits outweighs risk-FDA staff

(Adds detail, analyst comment)Oct 16 (Reuters) - The benefits of Novartis AG'santi-inflammation drug outweighed the risks in using it to treata type of psoriasis, staff reviewers at the U.S. Food and DrugAdministration said.The injectable biologic, secukinumab, ... [Published Reuters - Oct 16 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Cancer rates higher among patients with psoriasis

Share this article:Researchers analyzed cancer rates for different psoriasis treatments, but did not find a significantly greater risk associated with any particular therapy.Cancer rates higher in psoriasis patientsCancer rates appear higher in patients ... [Published The Clinical Advisor - Oct 17 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Study Suggest That Psoriasis Patients Have Increased Cancer Risk

Based on recently analyzed data from a retrospective analysis of commercial insurance claims, rates of cancer are higher in patients with psoriasis and that some anti-psoriatic drugs may pose a higher risk than others.Dr. Alexa B. Kimball of Massachusetts ... [Published CancerConnect.com - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Biologic Therapy With Topical Treatment in Psoriasis

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;1 ... [Published General Medicine eJournal - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Quality of life data on Celgene psoriasis drug Otezla

Having got the green light from US regulators last month, Celgene Corp has presented quality of life data on its oral psoriasis drug Otezla.New analysis of the ESTEEM 2 trial, presented at the European Academy of Dermatology and Venereology congress in ... [Published Pharma Times - Oct 13 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

New findings from the Psoriasis Longitudinal Assessment and registry (PSOLAR) show persistency difference among biologic therapies

Janssen has reported new findings at the annual meeting of the European Academy of Dermatology and Venereology (EADV) showing significantly better persistency and lower rates of discontinuation with STELARA(®) (ustekinumab) therapy in comparison to anti-tumor ... [Published Medical News Today - Oct 13 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 2 reports

Secukinumab Clears Skin of Psoriasis Patients in Phase III Trials

New analysis shows consistent efficacyNew phase III trial data have shown that treatment with 300 mg of secukinumab (AIN457, Novartis) resulted in higher rates of clear to almost-clear skin at week 12 compared with placebo, regardless of the patients’ ... [Published PT Community - Oct 10 2014]
First reported Oct 01 2014 - Updated Oct 02 2014 - 2 reports

Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The

THOUSAND OAKS, Calif. , Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel (etanercept) and ABP 501 (adalimumab biosimilar) at the 23 rd Congress of the European Academy ... [Published BioSpace - Oct 02 2014]
Entities: Amgen Inc, Psoriasis, Enbrel
First reported Sep 26 2014 - Updated Sep 26 2014 - 5 reports

Biosimilar Drug Developer Coherus BioSciences Files for IPO

- (c) 2014 Dow Jones & Company, Inc.Brian GormleyCoherus BioSciences Inc ., which is developing biosimilar versions of widely used biotechnology drugs such as Enbrel, has filed for an initial public offering with a maximum offering amount of $86.2 mi ... [Published Sofinnova Ventures - Sep 26 2014]

Quotes

...are currently no such limits defined for biosimilars; indeed, the EMA guidance on similar biological medicinal products 4 currently states that "The acceptance range to conclude clinical comparability with respect to any pharmacokinetic parameter"
...relationship clearing skin has on patients' quality of life," said Vasant Narasimhan, Global Head of Development, Novartis Pharmaceuticals. "With global regulatory approvals anticipated shortly, we hope to bring secukinumab to patients living with this debilitating disease, which impacts much more than their skin."
...stopping or switching treatment," said Dr Alan Menter, Chief, Division of Dermatology, Baylor University Medical Center, USA and lead investigator. "This particular analysis of the PSOLAR registry showed higher treatment longevity and lower rates of discontinuation with ustekinumab compared with anti-TNF-alpha agents."
[2] McLeod LD, Mallya UG, Fox T, Strober BE. "Psoriasis Patients With PASI 90 Response Achieve Greater Health-Related Quality-of-Life Improvements Than Those With PASI 75 Response." European Association of Dermatology and Venereology Congress. Amsterdam, Netherlands. 10 October 2014

More Content

All (148) | News (115) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (3) | Press Releases (0)
sort by: Date | Relevance
Regulated genes in psoriatic skin during treatm... [Published British Journal of Dermatology - Oct 18 2014]
New treatments help seniors live longer [Published NewsOK.com - Oct 18 2014]
Amgen Looks to Make Ebola Drug ZMapp With Hamst... [Published Washington Post - Oct 18 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Oct 17 2014]
RLO Announces Class Action Lawsuit By Enbrel Pa... [Published PRWeb - Oct 17 2014]
Amgen Tests New Way to Make Ebola Drug to Boost... [Published Bloomberg - Oct 17 2014]
Stock Update (NYSE:PFE): FDA panel votes to kee... [Published Jutia Group - Oct 17 2014]
Cancer rates higher among patients with psoriasis [Published The Clinical Advisor - Oct 17 2014]
Demonstrating Biosimilarity: PK Considerations [Published Applied Clinical Trials - Oct 16 2014]
Novartis' psoriasis drug looks good enough to a... [Published FierceBiotech - Oct 16 2014]
UPDATE 1-Novartis psoriasis drug benefits outwe... [Published Reuters - Oct 16 2014]
Study Suggest That Psoriasis Patients Have Incr... [Published CancerConnect.com - Oct 15 2014]
Spondyloarthritis Unifying Concepts to Improved... [Published General Medicine eJournal - Oct 15 2014]
A Quick Look at Pfizer Inc.'s Drug Development ... [Published Motley Fool Discussion Boards - Oct 14 2014]
Novartis announces data from analyses of Phase ... [Published Individual.com - Oct 14 2014]
Biologic Therapy With Topical Treatment in Psor... [Published General Medicine eJournal - Oct 14 2014]
Novartis Releases Data on Secukinumab for Plaqu... [Published Zacks.com - Oct 13 2014]
Stock Update (NYSE:PFE): Pfizer Announces FDA A... [Published Jutia Group - Oct 13 2014]
New findings from the Psoriasis Longitudinal As... [Published Medical News Today - Oct 13 2014]
Quality of life data on Celgene psoriasis drug ... [Published Pharma Times - Oct 13 2014]
Free medical clinic moves to new home in Newton [Published New Jersey Herald - Oct 12 2014]
Future looks very clear for Novartis psoriasis ... [Published Pharma Times - Oct 11 2014]
Secukinumab Clears Skin of Psoriasis Patients i... [Published PT Community - Oct 10 2014]
Novartis' secukinumab has 'consistent' activity... [Published PMLive - Oct 10 2014]
Novartis data at EADV show consistent efficacy ... [Published Noodls - Oct 10 2014]
Novartis data at EADV show consistent efficacy ... [Published BusinessWeek - Oct 10 2014]
Novartis data at EADV show consistent efficacy ... [Published SPi World News - Oct 10 2014]
Aiming for Remission in Psoriatic Arthritis [Published General Medicine eJournal - Oct 10 2014]
Biological Drugs Market Will Reach $287.14 Bill... [Published Crawford Financial Planning - Oct 09 2014]
The Percentage Of Rheumatoid Arthritis Patients... [Published A.M. Best - Oct 08 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Amgen Announces Moderate-To-Severe Plaque Psori... [Published PR Newswire: General Business - Oct 01 2014]
THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel® (etanercept) and ABP 501 (adalimumab biosimilar) at the 23rd Congress of the European Academy ...
RheumReports: Swollen Ears and Enbrel (CME/CE) [Published MedPageToday.com - medical news plus CME for ph ... - Sep 22 2014]
(MedPage Today) -- A 46-year-old man with ankylosing spondylitis started treatment with etanercept. His back pain improved -- but then his ears began to swell. Welcome to the rheumatologist's strange world. ...
Lilly's Ixekizumab proves superior in Phase 3 P... [Published PBR - News - Aug 22 2014]
Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe ...
Lilly's Ixekizumab Superior to Etanercept and P... [Published PR Newswire: Health - Aug 21 2014]
INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque psoriasis program to dateIxekizumab was superior to etanercept ...
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.